RNS Number : 7713D
Kromek Group PLC
19 November 2026

19 November 2026

Kromek Group plc
("Kromek" or the "Group")

Kromek receives £2.5m order from UK Ministry of Defence
New order for nuclear radiation detectors to be delivered in current financial year

Kromek Group plc (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, is pleased to announce that it has received an order worth £2.5m from the UK Ministry of Defence ("MOD") for the supply of nuclear radiation detectors. The contract is to be delivered in the Group's current financial year ending 30 April 2027.

The order is for the supply of the Group's D5 RIID, a high performance and versatile radiation detection device in a wearable package. This is the Group's second order from the MOD for the D5 RIID.

Arnab Basu, CEO of Kromek, said: "We are delighted to have secured another order from the UK MOD, which reinforces our position as a trusted partner in national defence as well as the market-leading nature of our solutions. This sizable order, for delivery in the current financial year, will make an important contribution to our continued growth in the CBRN Detection division. We look forward to fulfilling this order and to continuing to strengthen our relationship with this significant strategic customer."

For further information, please contact:

Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub — https://investors.kromek.com/link/PZpNne

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Claire Burgess, CFO

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker – Corporate Finance — +44 (0)20 7220 0500
Michael Johnson – Sales

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury — +44 (0)20 4582 3500

Engage with the Kromek management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our interactive investor hub here: https://investors.kromek.com/

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBVLLFQFLFFBL